These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 28247199)

  • 21. Economic Evaluation of the Combined Use of Warfarin and Low-dose Aspirin Versus Warfarin Alone in Mechanical Valve Prostheses.
    El-Hamamsy MH; Elsisi GH; Eldessouki R; Elmazar MM; Taha AS; Awad BF; Elmansy H
    Appl Health Econ Health Policy; 2016 Aug; 14(4):431-440. PubMed ID: 27028445
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential clinical and economic outcomes of CYP2C9 and VKORC1 genotype-guided dosing in patients starting warfarin therapy.
    You JH; Tsui KK; Wong RS; Cheng G
    Clin Pharmacol Ther; 2009 Nov; 86(5):540-7. PubMed ID: 19571807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost-effectiveness of rivaroxaban versus warfarin for treatment of nonvalvular atrial fibrillation in patients with worsening renal function.
    Salcedo J; Hay JW; Lam J
    Int J Cardiol; 2019 May; 282():53-58. PubMed ID: 30518479
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of pharmacogenomic-guided warfarin treatment for elderly Croatian atrial fibrillation patients with ischemic stroke.
    Mitropoulou C; Fragoulakis V; Bozina N; Vozikis A; Supe S; Bozina T; Poljakovic Z; van Schaik RH; Patrinos GP
    Pharmacogenomics; 2015 Jan; 16(2):137-48. PubMed ID: 25616100
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-effectiveness of rivaroxaban compared to warfarin for stroke prevention in atrial fibrillation.
    Lee S; Anglade MW; Pham D; Pisacane R; Kluger J; Coleman CI
    Am J Cardiol; 2012 Sep; 110(6):845-51. PubMed ID: 22651881
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
    O'Brien CL; Gage BF
    JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Novel oral anticoagulants versus warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis.
    You JH
    J Gen Intern Med; 2014 Mar; 29(3):438-46. PubMed ID: 24132628
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of non-vitamin K antagonist oral anticoagulants for stroke prevention in patients with atrial fibrillation at high risk of bleeding and normal kidney function.
    Hernandez I; Smith KJ; Zhang Y
    Thromb Res; 2017 Feb; 150():123-130. PubMed ID: 27771008
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-Utility Study of Warfarin Genotyping in the VACHS Affiliated Anticoagulation Clinic of Puerto Rico.
    Martes-Martinez C; Méndez-Sepúlveda C; Millán-Molina J; French-Kim M; Marín-Centeno H; Rivera-Miranda GC; Hernández-Muñoz JJ; Duconge-Soler J
    P R Health Sci J; 2017 Sep; 36(3):165-172. PubMed ID: 28915306
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cost-effectiveness of dabigatran compared with warfarin for patients with atrial fibrillation in Sweden.
    Davidson T; Husberg M; Janzon M; Oldgren J; Levin LÅ
    Eur Heart J; 2013 Jan; 34(3):177-83. PubMed ID: 22733833
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation.
    Coyle D; Coyle K; Cameron C; Lee K; Kelly S; Steiner S; Wells GA
    Value Health; 2013 Jun; 16(4):498-506. PubMed ID: 23796283
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-utility analysis of oral anticoagulants for nonvalvular atrial fibrillation patients at the police general hospital, Bangkok, Thailand.
    Jarungsuccess S; Taerakun S
    Clin Ther; 2014 Oct; 36(10):1389-94.e4. PubMed ID: 25267360
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Cost effectiveness of rivaroxaban for stroke prevention in German patients with atrial fibrillation.
    Mensch A; Stock S; Stollenwerk B; Müller D
    Pharmacoeconomics; 2015 Mar; 33(3):271-83. PubMed ID: 25404426
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of pharmacist-participated warfarin therapy management in Thailand.
    Saokaew S; Permsuwan U; Chaiyakunapruk N; Nathisuwan S; Sukonthasarn A; Jeanpeerapong N
    Thromb Res; 2013 Oct; 132(4):437-43. PubMed ID: 24041634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness of dabigatran compared with warfarin for stroke prevention in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Kamel H; Johnston SC; Easton JD; Kim AS
    Stroke; 2012 Mar; 43(3):881-3. PubMed ID: 22308255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cost-effectiveness of different strategies for stroke prevention in patients with atrial fibrillation in a health resource-limited setting.
    Wu B; Kun L; Liu X; He B
    Cardiovasc Drugs Ther; 2014 Feb; 28(1):87-98. PubMed ID: 24048510
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stroke prevention in patients with atrial fibrillation in France: comparative cost-effectiveness of new oral anticoagulants (apixaban, dabigatran, and rivaroxaban), warfarin, and aspirin.
    Lanitis T; Cotté FE; Gaudin AF; Kachaner I; Kongnakorn T; Durand-Zaleski I
    J Med Econ; 2014 Aug; 17(8):587-98. PubMed ID: 24831811
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation in Taiwan.
    Chang CH; Yang YH; Chen JH; Lin LJ
    Thromb Res; 2014 May; 133(5):782-9. PubMed ID: 24642004
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing.
    Meckley LM; Gudgeon JM; Anderson JL; Williams MS; Veenstra DL
    Pharmacoeconomics; 2010; 28(1):61-74. PubMed ID: 20014877
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Economic appraisal of dabigatran as first-line therapy for stroke prevention in atrial fibrillation.
    Bergh M; Marais CA; Miller-Jansön H; Salie F; Stander MP
    S Afr Med J; 2013 Feb; 103(4):241-5. PubMed ID: 23547700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.